CD274 and neoplasm: To demonstrate the value and improvements in outcomes that anti-PD-(L)1 therapy has brought to advanced/metastatic cancer patients in clinical practice, there is a need to understand available real-world evidence on the overall survival (OS) of patients with specific tumor types who would currently be eligible for treatment with an anti-PD-(L)1 agent but were treated with conventional care before the regulatory approval of anti-PD-(L)1 therapy and of patients treated with anti-PD-(L)1 agents after their approval by performing a systematic literature review (SLR).